Verndari
Napa, US · Founded 2015 · Delaware corporation
Verndari develops the VaxiPatch, a single-dose vaccination kit that uses intradermal microarray technology for vaccine delivery. The company focuses on vaccine delivery methods designed to be pain-free and thermostable, with pre-clinical studies indicating higher efficacy than traditional delivery.
Founders & leadership
Verndari was founded in 2015 by Daniel R. Henderson.
Board
JA
Jan A. Van ProoyenBoard director
Reported raises · per SEC filings
Form D private placements$1.6M disclosed across 1 round · 2016
▶$1.6MraisedFeb 2017 · 19 investors · PharmaceuticalsRule 506(b)
▶$1.6MraisedFeb 2017 · 19 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- John H. BrownExecutive Officer
- Daniel R. HendersonExecutive Officer, Director
- Jan A. Van ProoyenDirector
- Offering amount
- $2M
- Amount sold
- $1.6M
- Minimum investment
- $1
- First sale
- Jan 2016
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlap
Companies competing with Verndari for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Verndari do?
- Verndari develops the VaxiPatch, a single-dose vaccination kit that uses intradermal microarray technology for vaccine delivery. The company focuses on vaccine delivery methods designed to be pain-free and thermostable, with pre-clinical studies indicating higher efficacy than traditional delivery.
- Who founded Verndari?
- Verndari was founded by Daniel R. Henderson in 2015.
- How much funding has Verndari raised?
- Verndari has disclosed $1.6M raised across 1 round.
- Where is Verndari headquartered?
- Verndari is headquartered in Napa, US.